Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma

L. Chen, F. Pastorino, P. Berry, J. Bonner, C. Kirk, K.M. Wood, H.D. Thomas, Y. Zhao, A. Daga, G.J. Veal, J. Lunec, D.R. Newell, M. Ponzoni, D.A. Tweddle

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)3146-3159
Number of pages14
JournalInternational Journal of Cancer
Volume144
Issue number12
DOIs
Publication statusPublished - 2019

Cite this

Chen, L., Pastorino, F., Berry, P., Bonner, J., Kirk, C., Wood, K. M., Thomas, H. D., Zhao, Y., Daga, A., Veal, G. J., Lunec, J., Newell, D. R., Ponzoni, M., & Tweddle, D. A. (2019). Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. International Journal of Cancer, 144(12), 3146-3159. https://doi.org/10.1002/ijc.32058